Loading patent…
AssigneeJunten Bio Co., Ltd.
InventorsKoichiro Uchida, Kazuyoshi Takeda, Ko Okumura
Estimating the term…
The present disclosure provides a pharmaceutical composition for antigen-specific immune tolerance or immune suppression. The present disclosure provides a pharmaceutical composition comprising a CD4-positive anergy T cell and a CD8-positive anergy T cell. In some embodiments, the anergy T cell is induced by an antibody capable of inhibiting the interaction between CD80 and/or CD86 and CD28. In a specific embodiment, the pharmaceutical composition may additionally comprise a regulatory T cell (e.g., a FOXP3-positive CD4-positive CD25-positive T cell).
-57. (canceled)
A method of treating or preventing a disease, disorder, or condition in a subject caused by an antigen derived from the subject or an antigen that is not derived from the subject, comprising administering to the subject an effective amount of a CD4 positive anergic T cell and a CD8 positive anergic T cell.
A method of treating or preventing a disease, disorder, or condition in a subject caused by an antigen derived from the subject or an antigen that is not derived from the subject, the method comprising administering to the subject an effective amount of a cell having anergy induced by an inhibitory factor that can inhibit an interaction between CD80 and/or CD86 and CD28, wherein the anergy induced cell comprises a CD8 positive cell, and wherein the anergy-induced cell comprises at least one of a FOXP3 positive cell and a CD4 positive cell.
Dependencies are inferred from the claim text.